Tagged with hungary

Hungary Attila Lukács, general manager Hungary, Romania, Bulgaria for CSL Behring outlines emergent trends in the Hungarian plasma medication market, how the affiliate has succeeded in becoming a partner to patient associations in Hungary, and his strategic priorities for the future.   What I am most proud of is how we…

Hungary Laszlo Dinca, managing director of Vanessa Research – Hungary, shares his insights on the company’s rare and orphan disease portfolio; the intentions behind the acquisition of Hungaro-Gal Pharmaceutical Manufacturing [HG Biotech]; Hungary as a development market for biotechnology companies; and the future objectives of the company.   It is paramount…

Hungary Irma Veberic, general manager of Roche Hungary, gives her insights on the key issues being faced by the Hungarian healthcare system and the company’s role as a partner in improving health outcomes and raising life expectancy in the country. Veberic goes on to highlight the affiliate’s strong contribution to Hungary…

Hungary István Peták, co-founder and CEO of Oncompass introduces the innovative start-up and elaborates on how its solution for digital treatment planning and digital biomarkers can revolutionize not only personalized oncology treatment for patients, but also be a key tool in accelerating the clinical development of new targeted therapies.   The…

Hungary Dr Miklós Kellermayer elaborates on his priorities to implement a more practical, experience-focused curriculum as the recently appointed Dean of the Faculty of Medicine of Semmelweis University. Dr Kellermayer goes on to speak about the university’s critical role within the Hungarian healthcare ecosystem and the initiatives taking place during the…

Hungary Veronika Ferencz, general manager of Exeltis Hungary, gives an update on the recent activies and achievement of the affiliate since her last PharmaBoardroom interview in 2016. Furthermore, Ferencz goes on to highlight how the upcoming launch of the company’s first innovative product Slinda® is a very significant step in its…

Hungary István Hodász, CEO of Egis Pharmaceuticals PLC, introduces the longstanding history of the company and its positioning as a leading manufacturer of value-added generics with a strong presence in the CEE market. Hodász goes on to highlight the company’s recent milestones, including manufacturing investments, portfolio acquisitions, new therapeutic area strategies,…

Hungary Prof. Éva Szökő, president of the Hungarian Society for Pharmaceutical Sciences (MGYT), shares her insights on the activities of the society, its collaboration with institutions and industry players in the area of prevention, adherence, public health awareness, translational research, and its future outlook.   [Hungarian] patients are suspicious of prescribed…

Hungary Jānis Meikšāns, newly appointed general manager of Teva Hungary, speaks about his first few months in the country. Meikšāns goes on to elaborate on Hungary’s key positioning as a strategic affiliate for Teva with strong R&D and manufacturing operations. Additionally, he highlights Teva’s longstanding commitment to the country not only…

Hungary Dr Mátyás Szentiványi, Director General of the National Institute of Pharmacy and Nutrition (OGYEI), introduces the administrative authority and specifies his strategy to be an increasingly collaborative and communicative body of Hungary’s health regulation framework. Dr Szentiványi also goes on to comment on the current key challenges facing the sector,…

Hungary Dr. Péter Ofner, Former Director of the Gottsegen Hungarian Insititute of Cardiology, shares his insights on the cardiological capabilities of the institute, the epidemiological profile of the country, the collaborations with industry players, and outlooks for the future of this field as well as the country.   Hungary is a…

Hungary Dr. György Blaskó, former President and Chairman of the Hungarian European Clinical Research Infrastructure Network, explains the role of the research network, the impact it has on the Hungarian clinical research environment, and the areas of improvement moving forward.   Domestic centralized health care and the presence of a single…